Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 2, 2024Open Access

Sodium-glucose co-transporter 2 Inhibitors Act Independently of SGLT2 to Confer Benefit for Heart Failure with Reduced Ejection Fraction in Mice

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJustin H. BergerTMTimothy MatsuuraCBCaitlyn E. Bowman

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Berger et al. (2024) studied this question.

synapsesocial.com/papers/68e6bbe0b6db64358763ccfahttps://doi.org/10.1101/2024.04.29.591665
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure2017 · 344 citations
  2. 2Use of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure Without Diabetes2026
  3. 3Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure2024 · 6 citations
  4. 4Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure2020 · 28 citations
  5. 5The Role of SGLT2 Inhibitors on Treatment of Heart Failure, Mode of Actions2024 · 1 citations